Open AccessTreatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation
Author(s) -
Signe Sørup,
Bianka Darvalics,
Azza Ahmed Khalil,
Marianne Nordsmark,
Mette Hæe,
Frede Donskov,
Mads Agerbæk,
Leo Russo,
Dina Oksen,
Emmanuelle Boutmy,
Patrice Verpillat,
Deirdre CroninFenton
Publication year - 2021
Publication title -
clinical epidemiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.868
H-Index - 58
ISSN - 1179-1349
DOI - 10.2147/clep.s326470
Subject(s) - medicine , oncology , lung cancer , cancer , hazard ratio , adenocarcinoma , kidney cancer , renal cell carcinoma , confidence interval
Few studies have described real-world treatment patterns and survival before the widespread use of immune checkpoint inhibitors (ICIs). We aimed to describe anti-cancer treatment including the use of programmed cell death-1 and ligand-1 (PD-1/PD-L1) ICIs and overall survival (OS) in advanced cancer patients as a benchmarking real-world standard before widespread use of ICIs.